What is a HER2-positive in breast cancer in 2018?

被引：0
|
作者：
Schnitt, S. [1 ]
机构：
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-ES1-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES1-1
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [2] ASCO 2018: highlights in HER2-positive metastatic breast cancer
    Bartsch R.
    Bergen E.
    memo - Magazine of European Medical Oncology, 2018, 11 (4) : 280 - 283
  • [3] Treatment of advanced HER2-positive breast cancer: 2018 and beyond
    Ponde, Noam
    Brandao, Mariana
    El-Hachem, Georges
    Werbrouck, Emilie
    Piccart, Martine
    CANCER TREATMENT REVIEWS, 2018, 67 : 10 - 20
  • [4] What lies beyond APHINITY for HER2-positive breast cancer?
    Sasha E. Stanton
    Nancy E. Davidson
    Nature Reviews Clinical Oncology, 2017, 14 : 715 - 716
  • [5] What lies beyond APHINITY for HER2-positive breast cancer?
    Stanton, Sasha E.
    Davidson, Nancy E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (12) : 715 - 716
  • [6] Treatment of her2-positive breast cancer: What's on the horizon
    Dean-Colomb W.
    Esteva F.J.
    Current Breast Cancer Reports, 2010, 2 (1) : 42 - 52
  • [7] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [8] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [9] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326
  • [10] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
12345